RESALIS THERAPEUTICS S.R.L.

Obesity is one of the most prevalent chronic diseases in the world, yet available therapeutic options remain limited: drugs with significant side effects, invasive surgical interventions, and behavioral changes with high relapse rates. Resalis Therapeutics, founded in Turin, believes the solution lies at a biological level still largely unexplored: non-coding RNAs, molecules that regulate gene expression without being translated into proteins. Resalis' approach applies molecular biology to metabolic disorders. Non-coding RNAs play a crucial role in regulating the genes involved in metabolism, and their targeted modification opens the possibility of intervening at the root mechanisms driving obesity and other metabolic diseases. This is a young but scientifically grounded field that has already produced promising results in other therapeutic areas. Resalis' customers and partners include pharmaceutical companies, biotech firms, research centers, and — prospectively — clinicians involved in the development of RNA therapies. The franchising and operational partner support model suggests a co-development and licensing approach rather than an independent drug development path through regulatory approval. This choice is common among early-stage biotechs: it reduces capital requirements and accelerates external validation of the technology. Resalis operates in the RNA therapy market — a space that has seen extraordinary acceleration in recent years, driven in part by the success of mRNA vaccines during the pandemic. Investor and large pharma attention toward RNA-based therapies has grown significantly, creating favorable conditions for companies like Resalis that can bring credible pipelines to therapeutic areas with high unmet need, such as obesity.